Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denibulin - MediciNova

Drug Profile

Denibulin - MediciNova

Alternative Names: Denibulin di-hydrochloride; Denibulin-hydrochloride; MN-029

Latest Information Update: 30 May 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angiogene Pharmaceuticals
  • Developer MediciNova
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 13 Jan 2016 MediciNova receives patent allowance for denibulin in Europe
  • 16 Dec 2015 Denibulin is available for licensing in China (http://medicinova.com/)
  • 14 Dec 2015 MediciNova receives patent allowance for denibulin in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top